Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals Announces Closing of Registered Direct Offering
August 10th, 2008
Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) announced that it has completed the previously announced registered direct offering of 3,848,289 units (the "Units"), with each Unit consisting of (i) one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), and (ii) a warrant to purchase 0.45 of a share of Common Stock, for gross proceeds of approximately $26.0 million, before deducting placement agents' fees and estimated offering expenses. Lazard Capital Markets LLC served as lead placement agent and Leerink Swann LLC served as co-placement agent for the offering. The securities described above were offered by Jazz Pharmaceuticals pursuant to a...
Source: Pharma Investments, Ventures & Law Weekly (2008-08-10)
|
